home

 

Providing Targeted Cancer Diagnostics

About Us

UCL-Advanced Diagnostics is a non-commercial, specialist academic and clinical reference laboratory. Evolving from the Department of Pathology's Immunohistochemistry Unit, UCL-AD has been providing expert services to UCL Departments and UCL Hospitals since the early 1980s and to other hospitals around the UK since 1990. UCL-AD now stands as the immunohistochemistry, in situ and molecular diagnostics service arm of the UCL-Cancer Institute and a bridge between the Cancer Institute and University College Hospitals NHS Trust (UCLH). It is also the host laboratory for UKNEQAS ICC & ISH.

Modern personalised cancer treatments depend upon an accurate characterisation of the disease by both scientist and pathologist. There is an ever increasing array of biological and molecular markers available to assist in this, but it is not always cost effective for laboratories to hold a large portfolio of expensive markers. UCL-AD has one of the largest collections of antibodies and in situ probes in the country for use on formalin-fixed paraffin embedded tissue sections, and is a major centre for HER2 testing using both immunohistochemistry and in situ hybridisation (ISH). In addition, we test using a series of chromogenic in situ methods for infective agents, such as Cytomegalovirus (CMV), Epstein-Barr Virus (EBV) and various sub-types of Human Papilloma Virus (HPV). With the drive towards personalized, targeted cancer treatments, recent advances in diagnostic testing have seen the expansion of UCL-AD molecular diagnostic services to include validated tests EGFR, KRAS, NRAS and BRAF for lung, colorectal cancer and melanoma patients, together the analysis of the ALK and ROS1 fusion gene for lung cancer patients. In 2014 we seen the implementation of a translational program to bring rapid, cost effective TARGETED NEXT GENERATION SEQUENCING of cancer specific targets to clinical practice.

Our service is available on a permanent or temporary basis to all laboratories, pathologists, and oncologists whether they require a complete immunohistochemistry, in situ or molecular service, or just to complement their own local testing protocols with additional, specific biomarkers. We strongly believe that rapid, accurate and cost effective diagnostic testing; enabling assignment of targeted therapeutics should be available to all cancer patients, providing pathologists, oncologists and clinicians alike with the best possible tools to aid in the diagnostic and therapeutic decision making process.

Our IHC, in situ and molecular test lists highlight some of the more frequently requested biomarkers & probes, but do not encompass all the tests held by UCL-AD. If you do not see an antibody or probe or molecular target you require please do not hesitate to contact us.